



RADIOMOLECULAR PRECISION ONCOLOGY

FOR PATIENTS WORLDWIDE

THE ICPO FOUNDATION.

SPONSORSHIP PACKAGES AND PROGRAM ICPO THERANOSTICS VIRTUAL SUMMIT 2026

NOVEMBER 12 & 13, 2026

(VERSION JULY 2026)

CHAIRS



**Prof. Richard P.
Baum**



**Prof. Frederik L.
Giesel**



**Prof. Rudolf A.
Werner**

World-class programme:

Strong on multidisciplinary exchanges and patient focus covering 5 themes:

- Rising stars in Theranostics - Beyond PSMA and FAP
- Growing space of Alphas - Outlook on untapped potential
- Clinical trials planning - Navigate from hurdles to outcomes
- Leveraging AI in Theranostics - Advancing clinical practice globally
- Recommendations to grow patient access to Theranostics innovation over the next 5 years

MODERATORS



**Odile Jaume
CEO**



**Susanne Simon
Head of Communications**



**Pre-Register here:
www.icpo.foundation**

Day 1 - Nov 12, 2026 (CET)	Adopting new radiopharmaceuticals at your Theranostics center
2:00 - 2:15 pm	Welcome - Udo J. Vetter & Odile Jaume Programme overview by Chairs - Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner Keynote introduction – Susanne Simon
2:15 - 2:35 pm	KEYNOTE: From Imaging to Cure: Theranostics as a Core Pillar in Today's Oncology Toolbox – Michael Hofman
2:35 - 3:25 pm	SESSION I: Outlook into Next Gen emitters - Reminiscence of Y90 DOTATOC for NET – Richard P. Baum - Selection of optimal radionuclide: Efficacy and safety of Tb161 versus Lu177 – Cristina Mueller - Clinical potential of Tb161 for radioligand therapy – Damian Wild
3:25 - 4:25 pm	SESSION II: Clinical trends in Alpha corner - Ac225 insights in latest trials – Mike Sathekge - Latest clinical advances in Astatine (At211): Tadashi Watabe - Novel development and dosing strategies for alpha therapies, ADVC001 (Pb212) experience – Anna Karmann - Pb212 beyond prostate cancer – Michael Schultz
4.30 - 4:55 pm	PANEL 1: Alpha only approach: Potential & effectiveness? Benchmark with combination therapies? Moderators: Frederik L. Giesel and Rudolf A. Werner. Panelists: Ebrahim Delpassand, Cristina Müller, Mike Sathekge and Tadashi Watabe.
4:55 - 5:05 pm	BREAK
5:05 - 5:55 pm	SESSION III: Sunrise of FAP & other compounds on the horizon - FAP-based radiotheranostics for the treatment of diverse adenocarcinomas and sarcomas – Elisabetta Perrone - 3rd Generation of PSMA – Steven Rowe - Novel targets incl. CAIX, PL1 and others – Masato Murakami
5:55 - 6:40 pm	SESSION IV: Will “big” or “small” shape the future? What space for pre-targeting? - Perspective from radiopharmaceutical innovation – Jens Cardinale - Perspective from clinical radiochemistry – Jason Lewis - Perspective from translational nuclear medicine – Susanne Lütje
6:45 - 7:10 pm	PANEL 2: Is FAP revolutionary in terms of patient outcomes? Will it become the new gold standard for all Theranostics centers? Moderators: Richard. P. Baum and Frederik L. Giesel. Panelists: Jason Lewis, Sherly Mosessian, Masato Murakami, Steven Rowe.
7:10 - 7:15 pm	Wrap up and Closing of Day 1 Day 1 Impressions from Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner Closing - Odile Jaume & Susanne Simon

ICPO THERANOSTICS VIRTUAL SUMMIT 2026

NOVEMBER 12 & 13, 2026

**GROWING PATIENT ACCESS: ADOPTING NEW RADIOPHARMACEUTICALS
THERAPIES AND PLANNING FOR CLINICAL TRIALS**



Day 2 – Nov 13, 2026 (CET)	Planning and navigating clinical trials at your Theranostics center
10:00-10:05 am	Welcome - Odile Jaume Programme overview by Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner Keynote introduction – Susanne Simon
10:05-10:25 am	KEYNOTE: Future outlook into radiotheranostics - Ken Herrmann
10:25-11:15 am	SESSION V: Planning your clinical trial - Current and future design of theranostics clinical trials – Igor Rakovic - Structuring & managing trial data – Sam Vohra - Listening to patients advocates on clinical trials – Erik Briers
11:15-12:00 am	SESSION VI: Navigating trial design involving novel approaches - First use of Re188-PSMA, as Tc99m-PSMA companion: Mike Sathekge - uPAR-targeted PET imaging (muPA) tracers in oncology research – Andreas Kjaer - Role of Genomics & Transcriptomics or when in vitro meets in vivo – Ralph Wirtz
12:00-12:25 am	PANEL 3: Highlights of a PRRT Patient Journey and Lessons Learned Moderators: Frederik L. Giesel and Rudolf A. Werner. Panelists: Meredith Cummins, Ken Herrmann, Tiphaine Locqueneux, Igor Rakovic.
12:25-12:35 am	BREAK
12:35-1:25 pm	SESSION VII: How to reach and select patients for your trials? - Theranostics patient selection at large volume cancer center – Désirée Deandreis - Challenges and opportunities in patient recruitment for Theranostics in emerging research centers – Cecilia Carreras - Leveraging Ancora.ai radiopharmaceuticals trial finder – Danielle Ralic
1:25-2:15 pm	SESSION VIII: Leveraging AI in Theranostics at your center - Leveraging AI to advance clinical Theranostics globally – Johannes Tran-Gia - Empowering AI in clinical trials - Vikas Prasad - ARCHE: An AI-driven Curation and Harmonization Engine for Structuring Multimodal Theranostics Data – Lalith Sundar
2:15-2:40 pm	PANEL 4 / FINAL ROUND TABLE: Essential recommendations to grow patient access to radiotheranostics innovation over the next 5 years? Moderators: Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner. Panelists: Akram Al-Ibraheem, Desiree Deandreis, Vikas Prasad.
2:40-3:00 pm	Wrap up and closing of ICPO Summit 2026 Wrap up by Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner Closing by Odile Jaume and Susanne Simon

SPONSORSHIP CATEGORIES

We are delighted to invite you to consider participating as a sponsor of the **ICPO Theranostics Virtual Summit 2026**. Sponsoring the Summit offers your organization a meaningful opportunity to engage with a highly specialized international audience, contribute to the advancement of education and collaboration in Theranostics, and support an event that plays an important role leading the future of the field.

Below you will find an overview of the available sponsorship opportunities:

Title Category	Sponsorship Amount	Included in the Sponsorship Package
Title Sponsor	EUR 30K (excl. VAT)	60 free access for staff and external scientific collaborators Live participation in 1 session 2 min video played in breaks Logo displayed as Title Sponsor
Gold Sponsor	EUR 20K (excl. VAT)	40 free access for staff and external scientific collaborators 2 min video played in breaks Logo displayed as Gold Sponsor
Silver Sponsor	EUR 10K (excl. VAT)	20 free access for staff and external scientific collaborators Logo displayed as Silver Sponsor
Bronze Sponsor (limited to companies with up to 500 employees)	EUR 5K (excl. VAT)	10 free access for staff and external scientific collaborators Logo displayed as Bronze Sponsor
SME Sponsor (limited to companies with up to 50 employees)	EUR 2K (excl. VAT)	5 free access for staff and external scientific collaborators Logo displayed as SME Sponsor

We would be glad to discuss these options with you in more detail. Please feel free to contact **Juan Davila, Partner Engagement & Fundraising Director** at juan.davila@icpo.foundation to discuss the options.